AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22517351 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery presentation via the Internet
Number of subjects: 29
Study 20492573 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal soluble film (800 microg) administered as a single film
Number of subjects: 12
Study 20492573 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal soluble film (200 microg) administered as four separate films simultaneously
Number of subjects: 12
Study 20492573 — intervention group
Group type: COMPARATOR
Intervention: Injectable fentanyl citrate (200 microg) administered by intravenous infusion
Number of subjects: 12
Study 20492573 — intervention group
Group type: COMPARATOR
Intervention: Injectable fentanyl citrate (800 microg/16 mL) administered orally
Number of subjects: 12
Study 17694505 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (120 microg)
Number of subjects: 19
Study 17694505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 15912479 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week group (NT screening)
Number of subjects: 39572
Study 15912479 — intervention group
Group type: COMPARATOR
Intervention: 18-week group (maternal age-based screening)
Number of subjects: 39572
Study 12860904 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month exercise training program (T, n=45)
Number of subjects: 90
Study 12860904 — intervention group
Group type: COMPARATOR
Intervention: Control group (C, n=45)
Number of subjects: 90
Study 10520076 — intervention group
Group type: EXPERIMENTAL
Intervention: Active grass pollen immunotherapy
Number of subjects: 40
Study 10520076 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 40
Study 8904617 — intervention group
Group type: COMPARATOR
Intervention: 60 mg LY293111 three times daily for 8 days
Number of subjects: 24
Study 8904617 — intervention group
Group type: COMPARATOR
Intervention: 120 mg LY293111 three times daily for 8 days
Number of subjects: 24
Study 8904617 — intervention group
Group type: COMPARATOR
Intervention: 200 mg LY293111 twice daily for 8 days
Number of subjects: 24
Study 8904617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1825970 — intervention group
Group type: EXPERIMENTAL
Intervention: TRI/LNG
Number of subjects: 89
Study 1825970 — intervention group
Group type: EXPERIMENTAL
Intervention: GSD/30
Number of subjects: 89
Study 1825970 — intervention group
Group type: EXPERIMENTAL
Intervention: DOG/20
Number of subjects: 89
Study 6394044 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential treatment
Number of subjects: 0
Study 6394044 — intervention group
Group type: COMPARATOR
Intervention: Didactic treatment
Number of subjects: 0
Study 6394044 — intervention group
Group type: COMPARATOR
Intervention: Non-conscious treatment
Number of subjects: 0
Study 30844812 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 270
Study 30844812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 26802044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate Partner Violence (IPV) victimization
Number of subjects: 1339
Study 26802044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate Partner Violence (IPV) perpetration
Number of subjects: 1339
Study 26802044 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurrence of IPV victimization and perpetration
Number of subjects: 1339
Study 26802044 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with IPV
Number of subjects: 1339
Study 26802044 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related IPV perpetration
Number of subjects: 1339
Study 26802044 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender symmetry in IPV victimization
Number of subjects: 1339
Study 26887958 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal depression-oriented acupuncture (weekly 1-hour treatments for 8 weeks from 24 to 31 weeks of gestation)
Number of subjects: 96
Study 26887958 — intervention group
Group type: COMPARATOR
Intervention: Usual care (equivalent attention progressive muscle relaxation and routine antenatal depression hospital care)
Number of subjects: 96
Study 26887958 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal depression-oriented acupuncture
Number of subjects: 96
Study 24804638 — intervention group
Group type: EXPERIMENTAL
Intervention: Embrace Advanced Scar Therapy device
Number of subjects: 65
Study 24804638 — intervention group
Group type: COMPARATOR
Intervention: Surgeon's optimal care methods (control)
Number of subjects: 65
Study 22335426 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol XE 0.5%
Number of subjects: 50
Study 22335426 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 50
Study 20228401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy targeting systolic pressure <120 mm Hg
Number of subjects: 4733
Study 20228401 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy targeting systolic pressure <140 mm Hg
Number of subjects: 4733
Study 20228401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 4733
Study 20228401 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 4733
Study 17355281 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg suppository
Number of subjects: 490
Study 17355281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 490
Study 17355281 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 490
Study 15836564 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1000 mg)
Number of subjects: 401
Study 15836564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 12188410 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile extract spray (111 mg)
Number of subjects: 161
Study 12188410 — intervention group
Group type: COMPARATOR
Intervention: Normal saline spray (placebo)
Number of subjects: 161
Study 10650360 — intervention group
Group type: EXPERIMENTAL
Intervention: Periostat (subantimicrobial dose of doxycycline) in conjunction with scaling and root planing (SRP)
Number of subjects: 0
Study 10650360 — intervention group
Group type: COMPARATOR
Intervention: Placebo in conjunction with scaling and root planing (SRP)
Number of subjects: 0
Study 7889583 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA fentanyl
Number of subjects: 37
Study 7889583 — intervention group
Group type: COMPARATOR
Intervention: PCA morphine
Number of subjects: 37
Study 2240675 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms.ml‐1 (group C‐5)
Number of subjects: 92
Study 2240675 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 10 micrograms.ml‐1 (group C‐10)
Number of subjects: 92
Study 2240675 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 5 micrograms.ml‐1 (group E)
Number of subjects: 92
Study 2240675 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain lidocaine (group P)
Number of subjects: 92
Study 2240675 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine groups (C‐5 and C‐10)
Number of subjects: 92
Study 2240675 — intervention group
Group type: COMPARATOR
Intervention: Control group (plain lidocaine and epinephrine)
Number of subjects: 92
Study 30613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0
Study 30613 — intervention group
Group type: COMPARATOR
Intervention: Clemastine
Number of subjects: 0
Study 30613 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate
Number of subjects: 0
Study 30840026 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI FFR measurement
Number of subjects: 639
Study 27235128 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy (DC) and expansive duraplasty (ED) with hematoma evacuation (Group A)
Number of subjects: 40
Study 27235128 — intervention group
Group type: COMPARATOR
Intervention: Hematoma evacuation only (Group B)
Number of subjects: 40
Study 25514064 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmecamylamine (1 to 4 mg adjunct to SSRI/SNRI)
Number of subjects: 813
Study 25514064 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus SSRI/SNRI
Number of subjects: 813
Study 23435622 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin (500 mg/day) with docetaxel (75 mg/m²) and prednisone (10 mg daily)
Number of subjects: 14
Study 23435622 — intervention group
Group type: COMPARATOR
Intervention: Placebo with docetaxel (75 mg/m²) and prednisone (10 mg daily)
Number of subjects: 14
Study 22231005 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent tablets (Corega Tabs)
Number of subjects: 80
Study 22231005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic device (Ultrasonic Cleaner, model 2840 D)
Number of subjects: 80
Study 22231005 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of effervescent tablets and ultrasonic device
Number of subjects: 80
Study 22231005 — intervention group
Group type: COMPARATOR
Intervention: Brushing with water (Control)
Number of subjects: 80
Study 18801944 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee immobilizer
Number of subjects: 88
Study 18801944 — intervention group
Group type: COMPARATOR
Intervention: No knee immobilizer
Number of subjects: 88
Study 17439507 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (12 g/day, p.o.)
Number of subjects: 19
Study 17439507 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 g/day of maltodextrin, p.o.)
Number of subjects: 19
Study 17439507 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Oligofructose-enriched inulin and Placebo)
Number of subjects: 19
Study 15075413 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with dementia
Number of subjects: 176
Study 15075413 — intervention group
Group type: COMPARATOR
Intervention: Adults without dementia (controls)
Number of subjects: 176
Study 16749287 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mechanical revascularization with platelet glycoprotein IIb/IIIa inhibitors and drug-eluting stents, associated with strict glycemic control during hospital stay
Number of subjects: 0
Study 10548198 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 20 ppm for 20 minutes
Number of subjects: 12
Study 7485923 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 U/kg rHuEPO
Number of subjects: 49
Study 7485923 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 U/kg rHuEPO
Number of subjects: 49
Study 7485923 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 U/kg rHuEPO
Number of subjects: 49
Study 7485923 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U/kg rHuEPO
Number of subjects: 49
Study 7485923 — intervention group
Group type: COMPARATOR
Intervention: 0 U/kg rHuEPO (Control)
Number of subjects: 49
Study 1959392 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP treatment correcting apneas, sleep fragmentation, and hypoxemia
Number of subjects: 7
Study 1959392 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP treatment correcting apneas and sleep fragmentation while inducing intermittent hypoxemia
Number of subjects: 7
Study 1959392 — intervention group
Group type: COMPARATOR
Intervention: NCPAP treatment under hypoxemic conditions
Number of subjects: 7
Study 7265974 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclavian route
Number of subjects: 100
Study 7265974 — intervention group
Group type: COMPARATOR
Intervention: Internal jugular route
Number of subjects: 100
Study 31483408 — intervention group
Group type: EXPERIMENTAL
Intervention: FluoroSim training (5 attempts each week for 2 weeks)
Number of subjects: 45
Study 31483408 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 attempt 1 week apart for 2 weeks)
Number of subjects: 45
Study 28964563 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive parenting and consistent discipline
Number of subjects: 503
Study 28964563 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of positive parenting
Number of subjects: 503
Study 27234988 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician training intervention on the 5As framework (Ask, Advise, Agree, Assist, Arrange), consisting of four 1-hour training sessions
Number of subjects: 325
Study 27234988 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician training intervention on the 5As framework
Number of subjects: 325
Study 24239030 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim methadone (IM; methadone without counseling) for the first 4 months of 12 months of methadone treatment
Number of subjects: 200
Study 24239030 — intervention group
Group type: COMPARATOR
Intervention: 12 months of methadone with one of two counseling conditions
Number of subjects: 200
Study 24239030 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sample (both groups)
Number of subjects: 200
Study 22857721 — intervention group
Group type: EXPERIMENTAL
Intervention: Heme arginate (1 mg/kg body weight)
Number of subjects: 12
Study 22857721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20056720 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother and Baby (M&B) program (n=62)
Number of subjects: 161
Study 20056720 — intervention group
Group type: COMPARATOR
Intervention: Education only (EO) (n=73)
Number of subjects: 161
Study 17003815 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (non-pressor dose)
Number of subjects: 22
Study 17003815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15895356 — intervention group
Group type: COMPARATOR
Intervention: PEG
Number of subjects: 193
Study 11849459 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine betaine (GB) 4-g daily
Number of subjects: 36
Study 11849459 — intervention group
Group type: COMPARATOR
Intervention: Folate and pyridoxine alone
Number of subjects: 36
Study 11783251 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SQFZI) combined with chemotherapy (Group A)
Number of subjects: 120
Study 11783251 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Group B)
Number of subjects: 120
Study 11783251 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SQFZI) (Group C)
Number of subjects: 120
Study 7797977 — intervention group
Group type: COMPARATOR
Intervention: Splinting for 2 weeks following surgery
Number of subjects: 50
Study 7797977 — intervention group
Group type: EXPERIMENTAL
Intervention: Range-of-motion exercises starting on the first post-operative day
Number of subjects: 50
Study 2194894 — intervention group
Group type: EXPERIMENTAL
Intervention: 500-mL gastric bubble (Ballobes) as an adjunct to diet, physical training, and behavioral modification
Number of subjects: 0
Study 2194894 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study 2194894 — intervention group
Group type: COMPARATOR
Intervention: Very low-calorie diet and medical and dietary support
Number of subjects: 0
Study 30548268 — intervention group
Group type: EXPERIMENTAL
Intervention: My Time intervention
Number of subjects: 61
Study 30548268 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 61
Study 27377256 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity exercise
Number of subjects: 44
Study 27377256 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity exercise
Number of subjects: 44
Study 27377256 — intervention group
Group type: COMPARATOR
Intervention: Not meeting guidelines
Number of subjects: 44
Study 26865517 — intervention group
Group type: EXPERIMENTAL
Intervention: teriflunomide 14 mg
Number of subjects: 742
Study 26865517 — intervention group
Group type: EXPERIMENTAL
Intervention: teriflunomide 7 mg
Number of subjects: 742
Study 26865517 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 742
Study 26865517 — intervention group
Group type: EXPERIMENTAL
Intervention: teriflunomide (overall treatment)
Number of subjects: 742
Study 25029806 — intervention group
Group type: EXPERIMENTAL
Intervention: Asphyxiated newborns
Number of subjects: 93
Study 25029806 — intervention group
Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 93
Study 22344189 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 15
Study 22344189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex‐PRESS implantation
Number of subjects: 15
Study 22344189 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 15
Study 20679084 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA 1% (group A)
Number of subjects: 183
Study 20679084 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA 0.05% (group B)
Number of subjects: 183
Study 20679084 — intervention group
Group type: COMPARATOR
Intervention: Vehicle only (group C)
Number of subjects: 183
Study 17721997 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 L1E7 chimeric virus-like particles (CVLP) 75 mug
Number of subjects: 39
Study 17721997 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 L1E7 chimeric virus-like particles (CVLP) 250 mug
Number of subjects: 39
Study 17721997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 17721997 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 L1E7 chimeric virus-like particles (CVLP)
Number of subjects: 39
Study 15953223 — intervention group
Group type: EXPERIMENTAL
Intervention: Boussignac valve CPAP system
Number of subjects: 39
Study 15953223 — intervention group
Group type: COMPARATOR
Intervention: Drager CF800 CPAP system
Number of subjects: 39
Study 12468954 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilonium bromide (40 mg, three times daily)
Number of subjects: 378
Study 12468954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study 12468954 — intervention group
Group type: EXPERIMENTAL
Intervention: Otilonium bromide
Number of subjects: 378
Study 9661596 — intervention group
Group type: EXPERIMENTAL
Intervention: 192/192 genotype in Caucasian men with IOM
Number of subjects: 171
Study 9661596 — intervention group
Group type: COMPARATOR
Intervention: 192/192 genotype in healthy Caucasian men and women
Number of subjects: 171
Study 9661596 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with one 194-bp allele
Number of subjects: 171
Study 9661596 — intervention group
Group type: EXPERIMENTAL
Intervention: 192/192 genotype in men
Number of subjects: 171
Study 7662399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol education and intervention activities implemented by a state health department over three years.
Number of subjects: 11070
Study 7662399 — intervention group
Group type: COMPARATOR
Intervention: Comparison community (no intervention).
Number of subjects: 11070
Study 2583897 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-Phe (100 mg/kg) + UVA exposure
Number of subjects: 21
Study 2583897 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-Phe (100 mg/kg) + UVA exposure + topical 10% L-Phe cream
Number of subjects: 21
Study 848701 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation with oxygen and nitrogen
Number of subjects: 48
Study 848701 — intervention group
Group type: COMPARATOR
Intervention: Ventilation with oxygen and nitrous oxide
Number of subjects: 48
Study 30282100 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking event (3.5 km walking course including tasks such as crossing at the crosswalk, walking up- and downstairs without a railing, walking along dirt roads, and walking up and down a slope)
Number of subjects: 104
Study 30282100 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who could not participate in the walking event due to scheduling conflicts)
Number of subjects: 104
Study 26868513 — intervention group
Group type: EXPERIMENTAL
Intervention: Health intervention package (classroom-based health education, hand-held health record, health check)
Number of subjects: 388
Study 26868513 — intervention group
Group type: EXPERIMENTAL
Intervention: Health intervention package
Number of subjects: 388
Study 25459096 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen (NO)
Number of subjects: 20
Study 25459096 — intervention group
Group type: COMPARATOR
Intervention: Oxygen + oral analgesics
Number of subjects: 20
Study 24101747 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based course (MBC) with eight weekly sessions of mindfulness education
Number of subjects: 48
Study 24101747 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 24101747 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based course (MBC)
Number of subjects: 48
Study 20813123 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 68
Study 20813123 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 68
Study 17882008 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal patch releasing 14 microg of E2 per day
Number of subjects: 24
Study 17882008 — intervention group
Group type: COMPARATOR
Intervention: Vaginal ring releasing 7.5 microg of E2 per day
Number of subjects: 24
Study 15756271 — intervention group
Group type: COMPARATOR
Intervention: 350 mg m(‐2) irinotecan (Group A)
Number of subjects: 164
Study 15756271 — intervention group
Group type: EXPERIMENTAL
Intervention: 250, 350 or 500 mg m(‐2) irinotecan based on individual patient tolerance (Group B)
Number of subjects: 164
Study 15756271 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual dose escalation based on risk factor optimisation (Group C)
Number of subjects: 164
Study 12359676 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (to 60 mg/day)
Number of subjects: 52
Study 12359676 — intervention group
Group type: COMPARATOR
Intervention: Desipramine (to 30 mg/day)
Number of subjects: 52
Study 10367869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan, 1g intravenously
Number of subjects: 450
Study 10367869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin, 1g intravenously
Number of subjects: 450
Study 10367869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 7669541 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored preventive health program featuring health screening and smoking-cessation intervention
Number of subjects: 446
Study 2158257 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin 150 mg
Number of subjects: 406
Study 2158257 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin 300 mg
Number of subjects: 406